CO2021012240A2 - Conjugados de hialuronano y usos de estos - Google Patents

Conjugados de hialuronano y usos de estos

Info

Publication number
CO2021012240A2
CO2021012240A2 CONC2021/0012240A CO2021012240A CO2021012240A2 CO 2021012240 A2 CO2021012240 A2 CO 2021012240A2 CO 2021012240 A CO2021012240 A CO 2021012240A CO 2021012240 A2 CO2021012240 A2 CO 2021012240A2
Authority
CO
Colombia
Prior art keywords
hyaluronan
disclosed
hyaluronan conjugates
sex hormone
conjugates
Prior art date
Application number
CONC2021/0012240A
Other languages
English (en)
Inventor
Szu-Yuan Lee
Ping-Shan Lai
Chih-An Lin
Original Assignee
Aihol Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aihol Corp filed Critical Aihol Corp
Publication of CO2021012240A2 publication Critical patent/CO2021012240A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

RESUMEN En el presente documento se divulga un conjugado de hialuronano, que incluye un ácido hialurónico (AH), una hormona sexual y un enlazador para acoplar una de las unidades de disacárido del AH y la hormona sexual. También se divulgan en el presente documento los usos del conjugado hialuronano en el tratamiento o prevención de enfermedades neurodegenerativas.
CONC2021/0012240A 2019-06-03 2021-09-17 Conjugados de hialuronano y usos de estos CO2021012240A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962856714P 2019-06-03 2019-06-03
PCT/US2020/035780 WO2020247407A1 (en) 2019-06-03 2020-06-02 Hyaluronan conjugates and uses thereof

Publications (1)

Publication Number Publication Date
CO2021012240A2 true CO2021012240A2 (es) 2021-09-30

Family

ID=73550112

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0012240A CO2021012240A2 (es) 2019-06-03 2021-09-17 Conjugados de hialuronano y usos de estos

Country Status (15)

Country Link
US (2) US11524079B2 (es)
EP (2) EP3976019A4 (es)
JP (1) JP7275320B2 (es)
CN (1) CN113660933B (es)
AU (1) AU2020288834B2 (es)
BR (1) BR112021019113A2 (es)
CA (1) CA3133671C (es)
CO (1) CO2021012240A2 (es)
EA (1) EA202192225A1 (es)
IL (1) IL287917A (es)
MX (1) MX2021013140A (es)
SA (1) SA521430791B1 (es)
SG (1) SG11202109152UA (es)
TW (2) TWI737330B (es)
WO (2) WO2020247407A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024080183A1 (ja) * 2022-10-14 2024-04-18 国立大学法人東海国立大学機構 糖鎖複合体、薬物担体、及びドラッグデリバリーシステム
CN115970046B (zh) * 2022-12-02 2024-04-26 南京工业大学 一种多功能水凝胶在制备治疗糖尿病伤口药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002257430A1 (en) * 2001-05-01 2002-11-11 Mcgill University Androgen-mediated neuroprotection and uses thereof
AU2002951868A0 (en) * 2002-10-04 2002-10-24 Prana Biotechnology Limited Compound i
US8293890B2 (en) * 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
EP2468282A3 (en) * 2005-07-12 2012-09-12 DMI Biosciences, Inc. Methods and products for treatment of diseases
CA2616607C (en) 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
IE20060565A1 (en) * 2006-07-28 2008-02-06 Eurand Pharmaceuticals Ltd Drug delivery system based on regioselectively amidated hyaluronic acid
KR100806088B1 (ko) 2007-08-09 2008-02-21 고려대학교 산학협력단 히알루론산과 폴리에틸렌이민으로 이루어진 양이온성고분자 접합체를 이용한 핵산 전달용 조성물
IE20070900A1 (en) * 2007-12-12 2009-06-24 Eurand Pharmaceuticals Ltd New anticancer conjugates
WO2011148116A2 (fr) 2010-05-27 2011-12-01 Laboratoire Idenov Acide hyaluronique modifie, procede de fabrication et utilisations
US8895069B2 (en) 2011-05-16 2014-11-25 Postech Academy-Industry Foundation Drug delivery system using hyaluronic acid-peptide conjugate micelle
US20130116411A1 (en) 2011-09-06 2013-05-09 Allergan, Inc. Methods of making hyaluronic acid/collagen compositions
CN104603156B (zh) * 2012-09-05 2016-10-26 中外制药株式会社 引入有氨基酸和甾基的透明质酸衍生物
AU2014225682A1 (en) * 2013-03-08 2015-09-24 Allergan, Inc. Antibiotic conjugates linked with steroid drugs
EP2981556A4 (en) * 2013-04-02 2016-11-30 Univ California HYALURONIC ACID BIOPOLYMERS ETHYLSULFONATED AND METHODS OF USE
US9572832B2 (en) 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application
AU2015287696B2 (en) * 2014-07-10 2018-06-14 Academia Sinica Multi-drug delivery system and uses thereof
US20160279108A1 (en) * 2015-02-24 2016-09-29 University Of Kansas Targeted mtor inhibitors
KR101818705B1 (ko) 2015-07-20 2018-01-16 포항공과대학교 산학협력단 약물이 충전된 히알루론산 가교물 하이드로겔 및 이의 이용
US20190015518A1 (en) 2016-01-04 2019-01-17 University Of Kansas Drug delivery compositions and methods
CZ2016826A3 (cs) 2016-12-22 2018-07-04 Contipro A.S. Léčivý prostředek s nosičem na bázi hyaluronanu a/nebo jeho derivátů, způsob výroby a použití
TWI626043B (zh) * 2017-06-13 2018-06-11 心悅生醫股份有限公司 苯甲酸鋰用於治療中樞神經系統疾病的用途
TW201912152A (zh) * 2017-08-30 2019-04-01 保羅 L 曼弗雷蒂 用於治療或預防神經系統病症及其症狀及表現、以及用於對抗疾病及細胞老化及其症狀及表現之細胞保護之化合物

Also Published As

Publication number Publication date
IL287917A (en) 2022-01-01
TWI817065B (zh) 2023-10-01
EA202192225A1 (ru) 2022-03-15
EP3976019A1 (en) 2022-04-06
TW202110456A (zh) 2021-03-16
NZ779338A (en) 2024-04-26
WO2020247407A1 (en) 2020-12-10
US20200376132A1 (en) 2020-12-03
AU2020288834A1 (en) 2021-09-16
SG11202109152UA (en) 2021-12-30
AU2020288834B2 (en) 2022-12-22
CA3133671C (en) 2023-12-19
BR112021019113A2 (pt) 2021-12-14
JP2022539652A (ja) 2022-09-13
TWI737330B (zh) 2021-08-21
WO2021247076A1 (en) 2021-12-09
MX2021013140A (es) 2021-12-10
US20230080473A1 (en) 2023-03-16
EP4157256A4 (en) 2024-07-31
EP4157256A1 (en) 2023-04-05
US11524079B2 (en) 2022-12-13
CN113660933A (zh) 2021-11-16
EP3976019A4 (en) 2023-03-01
TW202146051A (zh) 2021-12-16
KR20210151062A (ko) 2021-12-13
SA521430791B1 (ar) 2024-07-15
JP7275320B2 (ja) 2023-05-17
CN113660933B (zh) 2023-12-01
CA3133671A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
CO2021012240A2 (es) Conjugados de hialuronano y usos de estos
GT200600297A (es) Nuevos anticuerpos anti-madcam
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
EA202090495A1 (ru) Производные 6-амино-7,9-дигидро-8h-пурин-8-она в качестве иммуностимулирующих агонистов toll-подобного рецептора 7 (tlr7)
UY37505A (es) Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico
CO2018002060A2 (es) Compuestos farmacéuticos
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
CO2023018231A2 (es) Restos de administración terapéutica novedosos y usos de estos
CL2022000729A1 (es) Derivado de heteroarilamidopiridinol y composición farmacéutica que comprende el mismo como ingrediente activo para prevención o tratamiento de enfermedad autoinmune
CO2023013465A2 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
CL2020002711A1 (es) Compuestos y sus usos para aliviar síntomas asociados a la menopausia
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
CL2018000131A1 (es) Inmunoconjugados de il22
NI201300045A (es) Inhibidores de apoptosis y usos de los mismos.
BR112015032529A2 (pt) composto de glicosaminoglicano e seu método de preparação, bem como sua aplicação
PH12020551994A1 (en) Tlr7 agonists
PE20151603A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos
CL2023000021A1 (es) Fármacos enlazadores y conjugados de anticuerpo-fármaco antifolato.
CL2020000508A1 (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.
EA201691964A1 (ru) Конъюгаты для доставки лекарственного средства для лечения устойчивой формы рака и для применения в комбинированной терапии
ECSP22049906A (es) Agonistas del tlr7